- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02478840
Evaluation of Long-term Efficacy of Treatment With Lamazym (rhLAMAN-10)
A Single Center, Open Label Clinical Trial Investigating the Long-term Efficacy of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) Treatment in Subjects With Alpha-Mannosidosis Who Previously Participated in Lamazym Trials
Study Overview
Detailed Description
The primary objective of the trial is to evaluate the impact of the long-term treatment with Lamazym upon the level of biomarker oligosaccharides in serum and upon the endurance as measured by the change from baseline in the number of steps climbed in 3 minutes (3MSCT).
As secondary objectives, the long term efficacy of Lamazym will be investigated upon endurance as measured by the change from baseline in the number of meters walked in six minutes (6MWT), upon pulmonary function, motor proficiency by BOT-2 and hearing capability by audiometry. In addition, cognitive development will be assessed by Leiter-R test. CNS involvement will be evaluated with MRI/MRS (for patients who previously participated in rhLAMAN-02 trial), CSF biomarkers (Tau, NFL, GFAp) and CSF biomarkers oligosaccharides. Clearance of oligosaccharides in urine will be measured.
Long-term safety and Pharmaco-Kinetic (PK) profile after long-term treatment as measured by rhLAMAN levels in plasma will be assessed as well.
Quality of life will be assessed by questionnaires (CHAQ and EQ-5D-5L).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, DK-2100
- Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject must have participated in the phase 1 trial (EudraCT number: 2010-022084-36), phase 2a trial (EudraCT number: 2010-022085-26), phase 2b trial (EudraCT number: 2011-004355-40) or phase 3 trial (EudraCT number: 2012-000979-17)
- The subject must still be receiving weekly intravenous infusions of Lamazym according to the AfterCare Program
- The Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities
- The subject and his/her guardian(s) must have the ability to comply with the protocol
Exclusion Criteria:
- History of bone marrow transplantation
- Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial. Subjects unable to perform the motor tests independently from support are permitted to participate in the trial and will be evaluated for the remnant non motor endpoints
- Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial
- Pregnant and/or lactating women cannot participate in the trial. Concerning women of child bearing potential (WOCBP), the investigators will decide whether or not there is a need for contraception. This assessment will be done through interviews with the patient and parents.
- Participation in other interventional trials testing IMP, including rhLAMAN-07 (EudraCT number: 2013-000336-97) and rhLAMAN-09 (EudraCT number: 2013-000321-31) trials with Lamazym
- Pause of the IMP for 2 consecutive weeks during the last month. Subjects are allowed to be re-screened
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Lamazym
1 mg Lamazym/kg Body weight
|
recombinant human alpha-mannosidase
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in reduction of oligosaccharides in serum
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Primary Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Change from baseline in 3 Minutes Stair Climb Test (3MSCT)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Primary Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6 Minute Walk Test (6MWT)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Pulmonary function: Forced Vital Capacity (FVC)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Pulmonary function: Forced Expiratory Volume during first second (FEV1)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Pulmonary function: Peak Expiratory Flow Rate (PEF)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Functional capacity according to Bruininks-Oseretsky test of Motor Proficiency (BOT-2)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Pure Tone Audiometry (PTA)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Equivalence age measured by Leiter International Performance Scale-Revised (Leiter-R)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Assessment of mannose-rich oligosaccharides in brain tissue as measured by Magnetic Resonance Spectroscopy (MRS) visual score (for patients who previously participated in rhLAMAN-02)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Assessment of mannose-rich oligosaccharides in brain tissue as measured by Magnetic Resonance Imaging (MRI) diffusion coefficient (for patients who previously participated in rhLAMAN-02)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Cerebrospinal fluid biomarkers: Oligosaccharides in Cerebrospinal Fluid (CSF)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Cerebrospinal fluid neuro-degeneration biomarkers: Tau Protein (Tau) in Cerebrospinal Fluid (CSF)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Cerebrospinal fluid neuro-degeneration biomarkers: Neurofilament Protein Light (NFL) in Cerebrospinal Fluid (CSF)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Cerebrospinal fluid neuro-degeneration biomarkers: Glial Fibrillary Acidic protein (GFAp) in Cerebrospinal Fluid (CSF)
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Endpoint evaluation as change
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Drug exposure by Pharmaco Kinetic (PK) sampling profile on plasma
Time Frame: 1 week
|
Evaluation of steady state Pharmaco Kinetics
|
1 week
|
Measurement of in vivo biological activity of Lamazym in blood before and after Infusion of Lamazym
Time Frame: 1 week
|
Comparing with Anti Body (AB) and PK measurements.
Measuring unit is mU/mL
|
1 week
|
Oligosaccharides in urine
Time Frame: 1 week
|
Evaluation of steady state
|
1 week
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life based on questionnaires
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
filled by the subject's guardian, will be evaluated by Childhood Health Assessment Questionnaire (CHAQ) questionnaires filled in by the subject's guardian, will be evaluated by CHAQ and EQ-5D-5L
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Quality of life based on questionnaires
Time Frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
filled by the subject's guardian, will be evaluated by Health Questionnaire (EQ-5D-5L) questionnaires filled in by the subject's guardian, will be evaluated by CHAQ and EQ-5D-5L
|
Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
|
Development of adverse events
Time Frame: 1 week
|
Safety endpoint assessed from signing of the Informed Consent Form (ICF)
|
1 week
|
Development of clinically significant changes in vital signs and change in physical examination
Time Frame: 1 week
|
Safety endpoint assessed throughout the trial
|
1 week
|
Development of clinically significant changes in the clinical laboratory Parameters: Hematology
Time Frame: 1 week
|
Safety endpoint assessed throughout the trial
|
1 week
|
Development of clinically significant changes in the clinical laboratory Parameters: Biochemistry
Time Frame: 1 week
|
Safety endpoint assessed throughout the trial
|
1 week
|
Development of clinically significant changes in the clinical laboratory Parameters: Urinalysis
Time Frame: 1 week
|
Safety endpoint assessed throughout the trial
|
1 week
|
Development of rhLAMAN antibodies
Time Frame: 1 week
|
Safety endpoint assessed throughout the trial
|
1 week
|
Development of rhLAMAN neutralizing/inhibitory antibodies
Time Frame: 1 week
|
Safety endpoint assessed throughout the trial
|
1 week
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Allan M Lund, MD, Copenhagen University Hospital, Center for Metabolic Diseases, Department of Clinical Genetics
- Study Chair: Jens M Fogh, DVM, Zymenex A/S
Publications and helpful links
General Publications
- Phillips D, Hennermann JB, Tylki-Szymanska A, Borgwardt L, Gil-Campos M, Guffon N, Amraoui Y, Geraci S, Ardigo D, Cattaneo F, Lund AM. Use of the Bruininks-Oseretsky test of motor proficiency (BOT-2) to assess efficacy of velmanase alfa as enzyme therapy for alpha-mannosidosis. Mol Genet Metab Rep. 2020 Apr 8;23:100586. doi: 10.1016/j.ymgmr.2020.100586. eCollection 2020 Jun.
- Borgwardt L, Guffon N, Amraoui Y, Jones SA, De Meirleir L, Lund AM, Gil-Campos M, Van den Hout JMP, Tylki-Szymanska A, Geraci S, Ardigò D, Cattaneo F, Harmatz P, Phillips D. Health Related Quality of Life, Disability, and Pain in Alpha Mannosidosis: Long-Term Data of Enzyme Replacement Therapy With Velmanase Alfa (Human Recombinant Alpha Mannosidase). Journal of Inborn Errors of Metabolism & Screening 2018, Volume 6: 1-12
- Lund AM, Borgwardt L, Cattaneo F, Ardigo D, Geraci S, Gil-Campos M, De Meirleir L, Laroche C, Dolhem P, Cole D, Tylki-Szymanska A, Lopez-Rodriguez M, Guillen-Navarro E, Dali CI, Heron B, Fogh J, Muschol N, Phillips D, Van den Hout JMH, Jones SA, Amraoui Y, Harmatz P, Guffon N. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis. J Inherit Metab Dis. 2018 Nov;41(6):1225-1233. doi: 10.1007/s10545-018-0175-2. Epub 2018 May 3.
- Harmatz P, Cattaneo F, Ardigo D, Geraci S, Hennermann JB, Guffon N, Lund A, Hendriksz CJ, Borgwardt L. Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-mannosidosis. Mol Genet Metab. 2018 Jun;124(2):152-160. doi: 10.1016/j.ymgme.2018.04.003. Epub 2018 Apr 18.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- rhLAMAN-10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alpha-Mannosidosis
-
Zymenex A/SEuropean CommissionUnknown
-
Zymenex A/SEuropean CommissionCompleted
-
Zymenex A/SEuropean CommissionCompletedAlpha MannosidosisCzechia, Germany, Norway, United Kingdom
-
CENTOGENE GmbH RostockWithdrawnAlpha-Mannosidase B Deficiency | Lysosomal Alpha B Mannosidosis | Alpha-Mannosidase DeficiencyIndia, Sri Lanka, Germany
-
Chiesi Farmaceutici S.p.A.CompletedAlpha-MannosidosisFrance
-
Zymenex A/SEuropean CommissionCompletedA Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-MannosidosisAlpha-MannosidosisDenmark, United Kingdom, France, Germany, Poland
-
Chiesi Farmaceutici S.p.A.Not yet recruiting
-
Chiesi Farmaceutici S.p.A.CromsourceCompletedAlpha-MannosidosisFrance, Denmark, Austria, Germany, Italy
-
Chiesi Farmaceutici S.p.A.Withdrawn
Clinical Trials on Lamazym
-
Chiesi Farmaceutici S.p.A.CromsourceCompletedAlpha-MannosidosisFrance, Denmark, Austria, Germany, Italy
-
Zymenex A/SEuropean CommissionCompleted
-
Zymenex A/SEuropean CommissionUnknown
-
Chiesi Farmaceutici S.p.A.CompletedAlpha-MannosidosisFrance
-
Chiesi Farmaceutici S.p.A.Completed
-
Zymenex A/SEuropean CommissionCompletedAlpha-MannosidosisBelgium, Denmark, Spain, United Kingdom
-
Zymenex A/SEuropean CommissionCompletedA Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-MannosidosisAlpha-MannosidosisDenmark, United Kingdom, France, Germany, Poland